A NEW device for the treatment of deep vein thrombosis (DVT) has been found by an Irish researcher to be highly effective and much faster than the standard treatment. Dr Gerard O'Sullivan, an ...

Giving the anti-clotting drug rivaroxaban to patients for 12 weeks instead of the usual six after a blood clot in the lower leg reduces the risk of further clots developing up to two years after ...

This week we are going to discuss two common conditions of the lower extremities which can be a cause for concern and the different strategies for managing them. Cellulitis is a infection of the ...

Deep vein thrombosis (DVT) is the subject of hundreds of medical studies worldwide. You might seek out clinical trials because your current DVT treatment isn’t working well. If you have a family ...

The disadvantages of dabigatran include a higher cost compared with warfarin, the need for twice-daily dosing, and a slightly increased risk for gastrointestinal bleeding (6.1% with dabigatran vs 4% ...

Philadelphia, PA The low molecular weight heparin, enoxaparin, given subcutaneously once or twice daily is as effective and safe as dose-adjusted, continuously infused unfractionated heparin in the ...

Deep vein thrombosis (DVT) is a blood clot that forms inside a vein deep in the body, whereas superficial thrombophlebitis (STP) is inflammation of the veins just below the skin’s surface. STP can ...

Penumbra reported positive data for a trial of its treatment for pulmonary embolism. The use of computer-assisted vacuum thrombectomy resulted in improvements in thrombus burden reduction, heart rate, ...

Key points A 53-year-old woman with rectosigmoid adenocarcinoma was seen in the radiation oncology clinic for her fifth and final fraction of neoadjuvant radiotherapy, where she reported chills, ...

For blood clots that cause heart attack and stroke, immediate treatment through surgical removal or dissolution with blood thinners can be life-saving. But what happens when a blood clot that causes ...

The first clinical use of heparin was for chemoprophylaxis in surgical patients. In 1937, Murray and Crafoord published data evaluating surgical patients who received prophylaxis for DVT. 14 Despite ...